For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Precaution Statements to Be Revised for Ketoprofen-Based OTC Drugs
November 1, 2010
- Takeda Sets Up Global Business Development Organization
November 1, 2010
- PMDA to Have Fewer Active Officials Dispatched from Korosho
November 1, 2010
- Daiichi Sankyo Healthcare Voluntarily Recalls Skin Cream
November 1, 2010
- PhRMA to Include Its Demand in US-Japan Talks for Regulatory Reform
October 25, 2010
- NICE Recommends Aricept for Mild AD
October 25, 2010
- Applications for Accreditation of Foreign Manufacturers Simplified
October 25, 2010
- Large Differences in Participation in Multinational Clinical Trials
October 25, 2010
- NDA Review Period Shortening in Japan: Mr Narita
October 25, 2010
- Indacaterol Significantly Improves Breathlessness: Novartis
October 25, 2010
- Korosho Requires Revisions of Package Inserts for Topical Ketoprofen
October 25, 2010
- 1st Gov't-Industry Meeting Held to Ensure Stable Supply of Mo-99
October 25, 2010
- Sales of Ethical Drugs Up 2.5% in August: Crecon Report
October 25, 2010
- Eli Lilly Japan to Target Orthopedic Surgeons in Promoting Forteo
October 25, 2010
- Continued Sales of Ketoprofen Products Should Be Permitted: CDFS
October 25, 2010
- Allermist Improves Ophthalmic Allergic Symptoms: Prof. Kurono
October 25, 2010
- CSO Market to Grow at 14.4% in FY2010 and Onward: MIC Research
October 25, 2010
- Original Itraconazole Product Shows Inter-Lot Differences
October 25, 2010
- 2 Kohdo-iryo Recommended for Use under Health Insurance Programs
October 25, 2010
- Price Settlement Rate 17.9% as of September at NPhA Members
October 25, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…